Personal Genome Diagnostics Appoints Jack Crowley as Chief Financial Officer

— CFO brings deep industry expertise and demonstrated results in life
sciences finance and operational leadership —

BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics,
announced that Jack Crowley has joined the company as Chief Financial
Officer. Mr. Crowley is a seasoned executive with extensive experience
overseeing finance organizations for Fortune 500 and private
equity-backed companies. He most recently served as CFO at Lantheus
Medical Imaging Inc., where he led the team through a successful
transition from a private equity-backed to a publicly-traded global life
sciences company.

We are thrilled to have Jack join PGDx as we continue to build the
management team and prepare for our next phase of growth,” said Doug
Ward, Chief Executive Officer. “Jack brings proven leadership in growing
healthcare companies and has been instrumental in providing the
financial vision and strategy to take organizations to the next level.
His experience will be invaluable as we continue to execute on our
strategic and operating plans and our commitment to delivering a
portfolio of regulated tissue and liquid biopsy genomic products to
laboratories worldwide.”

Mr. Crowley brings more than 25 years of finance and operations
experience to PGDx, previously serving as Chief Financial Officer and
Treasurer at Lantheus with responsibility for all finance, information
technology, and investor relationship activities. He led
transformational recapitalization efforts following Lantheus’ IPO in
2015, and his prior roles at the company included Chief Accounting
Offer, Vice President of Finance, and Global Corporate Controller.
Before joining Lantheus, Mr. Crowley served as Director of Finance and
Assistant Corporate Controller of Biogen Idec, the Director of
Accounting at Thermo Fischer Scientific, and a Senior Manager in the
Audit practice of PricewaterhouseCoopers LLP. Mr. Crowley, who is a
Certified Public Accountant, holds a Master of Business Administration
from the University of Massachusetts and a Bachelor of Science in
Business Administration from Westfield State University.

About Personal Genome Diagnostics
Personal Genome
Diagnostics (PGDx) empowers the fight against cancer by unlocking
actionable information from the genome. We are committed to developing a
portfolio of regulated tissue-based and liquid biopsy genomic products
for laboratories worldwide. PGDx was established by researchers from
Johns Hopkins University who are pioneers in cancer genome sequencing
and liquid biopsy technologies. For additional information, visit


PGDx Corporate:
Megan Bailey
Vice President, Marketing

W2O Group:
Peter Duckler
Director, Media

error: Content is protected !!